XML 48 R54.htm IDEA: XBRL DOCUMENT v3.19.3
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
USD ($)
item
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
License agreements                              
Long term investment             $ 117,902       $ 117,902     $ 99,199  
Research and development expense             281,336   $ 292,527   841,244 $ 893,719      
Unrealized gain (loss) on long term investments             2,339   (9,949)   18,703 (21,911)      
Current assets             2,319,595       2,319,595     1,832,254  
Current liabilities             461,683       461,683     425,277  
Cash and cash equivalents             1,702,023       $ 1,702,023     1,163,980  
Agenus                              
License agreements                              
Number of program targets | item       3   4                  
Royalty payments on future global net sales (as a percent)                     15.00%        
Upfront payment under license agreement           $ 60,000                  
Period of notice for termination of license agreement     12 months                        
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                     6.00%        
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                     12.00%        
Additional milestone payments under the license agreement     $ 510,000                        
Agenus | Development Milestones                              
License agreements                              
Upfront payment under license agreement                         $ 20,000    
Additional milestone payments under the license agreement                 5,000     5,000     $ 5,000
Agenus                              
License agreements                              
Long term investment             45,800       $ 45,800     42,300  
Research and development expense             $ 400   1,000   $ 1,300 3,800      
Shares owned following stock purchase (as a percent)     11.00%   9.00%                    
Ownership percentage (as a percent)             13.00%       13.00%        
Unrealized gain (loss) on long term investments             $ (7,500)   $ (2,300)   $ 3,500 $ (19,900)      
Total revenues               $ 15,700   $ 95,600          
Net income (loss)               $ (51,900)   $ (34,400)          
Agenus | Accrued and other liabilities                              
License agreements                              
Accrued and other liabilities             $ 2,200       $ 2,200     $ 2,300  
Agenus | Stock purchase agreement                              
License agreements                              
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                          
Purchase price of common stock   $ 60,000                          
Per share price | $ / shares $ 4.40 $ 6.00                          
Discount for lack of marketability $ 4,500                            
Fair value of shares on the issuance date 39,500                            
Total consideration paid $ 60,000                            
Long term investment                         39,500    
Research and development expense                         $ 20,500